Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X : a case report and literature review
2021 Annals of Translational Medicine. All rights reserved..
Asians who develop non-small cell lung cancer (NSCLC) have a chance of approximately 50% of harboring the epidermal growth factor receptor (EGFR) mutation. The G719X mutation in EGFR has 3 subtypes (i.e., G719A, G719C, or G719S), all of them being classified as uncommon EGFR mutations. The EGFR mutation G719X is most often associated with lung adenocarcinoma. Conversely, its occurrence in lung squamous cell carcinoma is rare. Its response to tyrosine kinase inhibitor (TKI) treatment remains unknown. A 50-year-old Asian male with no smoking history was admitted to our hospital (Affiliated Hospital of Qingdao University) with an irritating dry cough and 1 month of progressive dyspnea. The patient was diagnosed with lung squamous cell carcinoma (cT4N3M0, stage IIIC). Lung biopsy revealed the presence of EFGR G719X mutation. The patient received a tracheobronchial stent, targeted therapy, chemotherapy, seed implantation and radiotherapy, and survived for 25.4 months following diagnosis. It is crucial that gene mutation analysis is performed in non-smoking male squamous cell carcinoma patients. Compared to lung adenocarcinoma patients with rare G719X mutation, this lung squamous cell carcinoma patient with G719X-mutant tumor had a higher sensitivity to 2nd-generation EGFR-TKI treatment, but similar progression-free survival. Importantly, the patient clearly benefited from the used comprehensive treatment plan. This article seeks to shed light on the treatment of lung squamous cell carcinoma patients with the uncommon EGFR G719X mutation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Annals of translational medicine - 9(2021), 24 vom: 22. Dez., Seite 1805 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bi, Huanhuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 25.01.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/atm-21-6653 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336060564 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336060564 | ||
| 003 | DE-627 | ||
| 005 | 20231225231258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/atm-21-6653 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1120.xml |
| 035 | |a (DE-627)NLM336060564 | ||
| 035 | |a (NLM)35071499 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bi, Huanhuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X |b a case report and literature review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2021 Annals of Translational Medicine. All rights reserved. | ||
| 520 | |a Asians who develop non-small cell lung cancer (NSCLC) have a chance of approximately 50% of harboring the epidermal growth factor receptor (EGFR) mutation. The G719X mutation in EGFR has 3 subtypes (i.e., G719A, G719C, or G719S), all of them being classified as uncommon EGFR mutations. The EGFR mutation G719X is most often associated with lung adenocarcinoma. Conversely, its occurrence in lung squamous cell carcinoma is rare. Its response to tyrosine kinase inhibitor (TKI) treatment remains unknown. A 50-year-old Asian male with no smoking history was admitted to our hospital (Affiliated Hospital of Qingdao University) with an irritating dry cough and 1 month of progressive dyspnea. The patient was diagnosed with lung squamous cell carcinoma (cT4N3M0, stage IIIC). Lung biopsy revealed the presence of EFGR G719X mutation. The patient received a tracheobronchial stent, targeted therapy, chemotherapy, seed implantation and radiotherapy, and survived for 25.4 months following diagnosis. It is crucial that gene mutation analysis is performed in non-smoking male squamous cell carcinoma patients. Compared to lung adenocarcinoma patients with rare G719X mutation, this lung squamous cell carcinoma patient with G719X-mutant tumor had a higher sensitivity to 2nd-generation EGFR-TKI treatment, but similar progression-free survival. Importantly, the patient clearly benefited from the used comprehensive treatment plan. This article seeks to shed light on the treatment of lung squamous cell carcinoma patients with the uncommon EGFR G719X mutation | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a G719X | |
| 650 | 4 | |a Lung squamous cell carcinoma | |
| 650 | 4 | |a case report | |
| 650 | 4 | |a gene mutation | |
| 700 | 1 | |a Ren, Dunqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jieqiong |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Xiaoqian |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Caihong |e verfasserin |4 aut | |
| 700 | 1 | |a Miura, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Megyesfalvi, Zsolt |e verfasserin |4 aut | |
| 700 | 1 | |a Arulananda, Surein |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hongmei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of translational medicine |d 2013 |g 9(2021), 24 vom: 22. Dez., Seite 1805 |w (DE-627)NLM23455374X |x 2305-5839 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:24 |g day:22 |g month:12 |g pages:1805 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/atm-21-6653 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 24 |b 22 |c 12 |h 1805 | ||